VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two

Article Related Articles (1) Stock Quotes (3) Comments (0)

VIVUS (Nasdaq: VVUS) shares are higher on the session following improving payment metrics for its obesity drug Qsymia.

According to Bloomberg Industries, Qsymia's prescription insurer payment rate rose 5 points in its second week to 36 percent.

Initial estimates from the company called for a minimal initial coverage rate.

Bloomberg Industries noted that the news could be a boon for peer Arena Pharmaceuticals (Nasdaq: ARNA) and its Belviq. Traders are likely to keep an eye on Orexigen (Nasdaq: OREX), which is working on the weight-loss pill Contrave.

Shares of VIVUS are up 3 percent Monday.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Vivus (VVUS) Sees Upside on Icahn Connection
• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Sarissa Capital Shows New 1.99% Stake in Vivus, Inc. (VVUS), Denner Nominated to Board

Create E-mail Alert Related Categories

Analyst Comments, Trader Talk

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?